 "Novartis tanks 7% on losing patent battle over cancer drug Glivec")
Mumbai: Shares of Novartis India today plunged nearly 7 percent to hit a one-year low level on the BSE, after the Supreme Court dismissed Novartis AG’s plea for getting its blood cancer drug patented in India.
Following the move, shares of the company tanked 6.79 percent to Rs 558.10-its 52-week low despite a positive opening at the BSE. Swiss pharma major Novartis AG today lost a seven-year long legal battle for getting its blood cancer drug Glivec patented in India and to restrain Indian companies from manufacturing generic drugs, with the Supreme Court rejecting the multinational company’s plea.
Novartis had approached the apex court in 2009 against the order of Chennai-based Intellectual Property Appellate Board (IPAB), which had rejected its claim for patent. The multinational company (MNC) had applied for patent in 2006.
Among other drug companies, shares of Natco Pharma were trading higher by 4.20 percent, while Cipla rose by 2.28 percent in the late morning trade.
PTI
 "WATCH: Will Eli Lilly’s weight-loss drug be a gamechanger?")
 "Abu Dhabi seeks Indian investments, invites start-ups to establish hubs")
 "What is Active Pharmaceutical Ingredient and why is it essential for drug manufacturing?")
 "Fire not an 'act of God' if no external natural force involved, says Supreme Court")
 "WATCH: Will Eli Lilly’s weight-loss drug be a gamechanger?")
 "Abu Dhabi seeks Indian investments, invites start-ups to establish hubs")
 "What is Active Pharmaceutical Ingredient and why is it essential for drug manufacturing?")
 "Fire not an 'act of God' if no external natural force involved, says Supreme Court")